Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||DEC-205-NY-ESO-1 fusion protein vaccine|
DEC-205/NY-ESO-1 fusion protein vaccine constists of a monoclonal antibody directed against the dendritic cell receptor DEC-205 linked to the tumor-associated antigen DEC-205/NY-ESO-1 fusion protein. The vaccine may boost the immune system to attack cancer cells expressing DEC-205/NY-ESO-1 fusion protein (NCI Drug Dictionary).
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine||Atezolizumab DEC-205-NY-ESO-1 fusion protein vaccine||0||1|
|Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine + Guadecitabine||Atezolizumab DEC-205-NY-ESO-1 fusion protein vaccine Guadecitabine||0||1|
|DEC-205-NY-ESO-1 fusion protein vaccine||DEC-205-NY-ESO-1 fusion protein vaccine||0||4|
|DEC-205-NY-ESO-1 fusion protein vaccine + Decitabine||DEC-205-NY-ESO-1 fusion protein vaccine Decitabine||0||1|
|DEC-205-NY-ESO-1 fusion protein vaccine + Decitabine + Nivolumab + Poly ICLC||DEC-205-NY-ESO-1 fusion protein vaccine Decitabine Nivolumab Poly ICLC||0||1|